Advertisement
ABBV or PFE or VRTX
Which Stock Would AI Choose? AbbVie (ABBV) vs. Pfizer (PFE) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- ABBV exhibits strong recent momentum with shares up over 9% in the past month, driven by positive Phase 3 data for SKYRIZI in Crohn's disease and neuroscience growth.
- PFE leads YTD performance at around 8%, bolstered by obesity drug approvals in China, though it faces headwinds from declining COVID sales.
- VRTX shows solid Q4 revenue beats from cystic fibrosis drugs and pain management progress, but trails peers in YTD gains at about 1%.
- ABBV offers the highest dividend yield near 3%, appealing to income investors, while VRTX commands a premium valuation with a lower beta of 0.31.
- All three stocks demonstrate resilience in the pharma sector, with diversified pipelines offsetting patent and market challenges.
- Relative performance highlights ABBV's outperformance over the past year at ~13%, compared to PFE's ~4% and VRTX's flat returns.
Introduction
This stock comparison examines ABBV, PFE, and VRTX, three leading biopharmaceutical companies navigating patent cliffs, pipeline advancements, and sector shifts. Investors seeking exposure to immunology, oncology, and rare diseases, or traders eyeing relative performance in a volatile pharma market, will find value in their contrasting profiles. With recent catalysts like drug approvals and trial data influencing sentiment, this analysis highlights key metrics for informed decision-making in the current environment.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV), a research-based biopharmaceutical firm, focuses on immunology, oncology, neuroscience, and aesthetics. Its portfolio includes blockbusters like Skyrizi, Rinvoq, and Botox. In recent market activity, ABBV shares have risen about 9.7% over the past month and 2-3% YTD, trading around $230 with a market cap exceeding $400 billion. Positive Phase 3 results for SKYRIZI in Crohn's disease have bolstered its immunology franchise, while neuroscience sales hit $10.8 billion in 2025, up 20% year-over-year, driven by Vraylar and Vyalev. Sentiment benefits from resilient quarterly results and a 3% dividend yield, though high valuations around 97x trailing P/E and beta of 0.33 reflect stability amid broader pharma pressures.
PFE Overview and Recent Performance
Pfizer Inc. (PFE), a global leader in biopharmaceuticals, emphasizes oncology, obesity, and vaccines. Key products include those in its reshaped portfolio post-COVID. Recently, PFE shares have gained around 4.5% monthly and 8% YTD, hovering near $27 with a $154 billion market cap. Approval of its obesity drug Severwin in China marks a strategic pivot, offsetting declines in COVID-related revenues and patent losses. The stock's low 19.6x trailing P/E, 6.5% dividend yield, and beta of 0.47 position it as a value play, with pipeline progress in oncology fostering cautious optimism despite sector headwinds.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals Inc. (VRTX) specializes in transformative therapies for serious diseases, dominating cystic fibrosis with Trikafta and expanding into pain and Type 1 diabetes. Shares trade around $457, with a $116 billion market cap, up modestly YTD at ~1% but showing 5-6% monthly gains amid volatility. Q4 2025 revenues of $3.19 billion beat estimates, fueled by CF demand and Journavx pain data. Trading at a 29x P/E with no dividend and low beta of 0.31, VRTX appeals to growth investors, though recent insider sales and mixed sentiment temper enthusiasm versus peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases top-performing AI trading bots curated for current market conditions from hundreds of agents that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like trend-following, swing trading, and hedging, with timeframes from 5-minute to 60-minute intervals using technical and fundamental analyses. Highlighted trending bots display impressive stats: annualized returns from +14% to over +215%, win rates of 53% to 95%, and profit factors up to 25.83. Examples include AeroDefense bots at +32-63% annualized with 71-80% win rates in aerospace, and multi-ticker agents up +134% in minerals and semis. Explore these high-potential options tailored to volatility for enhanced trading edges.
Head-to-Head Comparison
ABBV, PFE, and VRTX operate in biopharma but diverge in models: ABBV's diversified immunology and neuroscience drive steady growth (7% LTM revenue), contrasting PFE's broad vaccines/obesity pivot amid post-COVID declines. VRTX excels in niche CF dominance with higher margins but narrower exposure. Momentum favors ABBV (9% monthly) over PFE (4.5%) and VRTX (5%), with risks from patents higher for PFE. Valuations show PFE cheapest (19x P/E), VRTX growth-premium (29x), ABBV elevated (97x) but yield-rich (3%). Lower betas (<0.5) across all signal defensive positioning versus broader pharma sentiment.
Tickeron AI Verdict
Tickeron’s AI currently favors ABBV due to superior recent momentum, pipeline catalysts like SKYRIZI and neuroscience expansion, and relative stability in trend consistency. While PFE offers value and yield, and VRTX growth potential, ABBV's positioning suggests higher probability of near-term outperformance amid pharma volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s), and VRTX’s FA Score reflects 0 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s), and VRTX’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
- VRTX’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.38% , and VRTX (@Biotechnology) price fluctuated -0.20% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.75%. For the same industry, the average monthly price growth was +4.38%, and the average quarterly price growth was +7.68%.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
PFE is expected to report earnings on May 05, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | PFE | VRTX | |
| Capitalization | 360B | 157B | 112B |
| EBITDA | 17.6B | 16.8B | 4.87B |
| Gain YTD | -7.305 | 12.373 | -3.128 |
| P/E Ratio | 85.95 | 20.24 | 28.67 |
| Revenue | 61.2B | 62.6B | 12B |
| Total Cash | N/A | 13.6B | 6.61B |
| Total Debt | 67.5B | 64B | 2.03B |
ABBV | PFE | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 34 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | 100 | 35 | |
SMR RATING 1..100 | 1 | 74 | 40 | |
PRICE GROWTH RATING 1..100 | 55 | 27 | 59 | |
P/E GROWTH RATING 1..100 | 40 | 34 | 53 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is in the same range as ABBV (35) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for VRTX (80) in the Biotechnology industry. This means that PFE's stock grew similarly to ABBV’s and somewhat faster than VRTX’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is in the same range as VRTX (35) in the Biotechnology industry, and is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to VRTX’s and significantly faster than PFE’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRTX (40) in the Biotechnology industry, and is significantly better than the same rating for PFE (74) in the Pharmaceuticals Major industry. This means that ABBV's stock grew somewhat faster than VRTX’s and significantly faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as ABBV (55) in the Pharmaceuticals Major industry, and is in the same range as VRTX (59) in the Biotechnology industry. This means that PFE's stock grew similarly to ABBV’s and similarly to VRTX’s over the last 12 months.
PFE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as ABBV (40) in the Pharmaceuticals Major industry, and is in the same range as VRTX (53) in the Biotechnology industry. This means that PFE's stock grew similarly to ABBV’s and similarly to VRTX’s over the last 12 months.
| ABBV | PFE | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | 4 days ago 63% | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 58% | 4 days ago 66% | 4 days ago 64% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 51% | 4 days ago 64% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 55% | 4 days ago 62% |
| TrendWeek ODDS (%) | 4 days ago 58% | 4 days ago 55% | 4 days ago 62% |
| TrendMonth ODDS (%) | 4 days ago 51% | 4 days ago 51% | 4 days ago 36% |
| Advances ODDS (%) | 12 days ago 57% | 4 days ago 56% | 7 days ago 63% |
| Declines ODDS (%) | 8 days ago 48% | 11 days ago 57% | 5 days ago 43% |
| BollingerBands ODDS (%) | 4 days ago 62% | 4 days ago 52% | N/A |
| Aroon ODDS (%) | 4 days ago 43% | 4 days ago 52% | 4 days ago 30% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AFMC | 38.54 | 0.15 | +0.39% |
| First Trust Active Factor Mid Cap ETF | |||
| PSK | 31.54 | -0.01 | -0.04% |
| Stt Strt® SPDR® ICE Preferred Secs ETF | |||
| OEF | 348.37 | -1.35 | -0.39% |
| iShares S&P 100 ETF | |||
| SKF | 27.17 | -0.15 | -0.55% |
| ProShares UltraShort Financials | |||
| UNHG | 14.34 | -0.09 | -0.62% |
| Leverage Shares 2X Long UNH Daily ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| PFE - ABBV | 57% Loosely correlated | +1.25% | ||
| BMY - ABBV | 55% Loosely correlated | +2.05% | ||
| BIIB - ABBV | 51% Loosely correlated | +0.76% | ||
| AMGN - ABBV | 51% Loosely correlated | +1.69% | ||
| NVS - ABBV | 49% Loosely correlated | +1.50% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.15% | ||
| MRK - PFE | 66% Loosely correlated | -1.65% | ||
| BMY - PFE | 64% Loosely correlated | -1.73% | ||
| BIIB - PFE | 61% Loosely correlated | +3.38% | ||
| AMGN - PFE | 58% Loosely correlated | -1.45% | ||
| NVS - PFE | 54% Loosely correlated | -0.64% | ||
More | ||||